8-K: Organogenesis Holdings Inc. Reports Mixed First Quarter 2024 Results, Reaffirms Full-Year Guidance

Organogenesis Holdings Inc. announced its first quarter 2024 financial results, showing a slight revenue increase but a decrease in adjusted EBITDA, while reaffirming its full-year 2024 guidance.

Summary

• Organogenesis Holdings Inc. reported a net revenue of $110.0 million for the first quarter of 2024, a 2% increase compared to $107.6 million in the same period of 2023.
• The company's Advanced Wound Care product revenue increased by 3% to $103.9 million, while Surgical & Sports Medicine product revenue decreased by 9% to $6.1 million.
• Net loss for the quarter was $2.1 million, an improvement from a $3.0 million loss in the first quarter of 2023.
• However, the adjusted net loss increased to $1.4 million from $0.7 million in the prior year's quarter.
• Adjusted EBITDA decreased to $2.6 million from $3.8 million in the first quarter of 2023.
• The company reaffirmed its full-year 2024 revenue guidance of $445.0 million to $470.0 million, representing a 3% to 9% year-over-year increase.
• The 2024 revenue guidance includes Advanced Wound Care revenue between $415.0 million and $435.0 million and Surgical & Sports Medicine revenue between $30.0 million and $35.0 million.
• The company expects a net loss between $10.6 million and $4.6 million and adjusted net loss between $8.1 million and $7.1 million for the full year.
• EBITDA is projected to be between $5.8 million and $25.0 million, and Adjusted EBITDA between $15.8 million and $35.0 million for the full year.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the revenue increase and reaffirmed guidance, but tempered by the decrease in adjusted EBITDA and the mixed performance across different segments. The company is facing some challenges but is generally on track.

Positives

• The company's net revenue increased by 2% year-over-year, reaching $110.0 million.
• The Advanced Wound Care segment showed a 3% revenue increase.
• The net loss decreased by $0.9 million compared to the same quarter last year.
• The company reaffirmed its full-year 2024 revenue guidance, indicating confidence in future performance.

Negatives

• The Surgical & Sports Medicine segment experienced a 9% decrease in revenue.
• The adjusted net loss increased by $0.8 million compared to the first quarter of 2023.
• Adjusted EBITDA decreased by $1.2 million compared to the same quarter last year.
• Cash, cash equivalents and restricted cash decreased from $104.3 million to $89.3 million since December 31, 2023.

Risks

• Changes in coverage and reimbursement levels for the company's products could impact revenue.
• The company faces significant competition, which could adversely affect its business.
• Rapid technological changes could make the company's products obsolete.
• The company's ability to raise funds to expand its business is a risk.
• The company has incurred losses and may incur losses in the future.
• The company's ability to maintain production or obtain supply of its products in sufficient quantities to meet demand is a risk.
• The company's ability to obtain regulatory approval for and successfully commercialize ReNu is a risk.

Future Outlook

The company reaffirmed its full-year 2024 guidance, expecting net revenue between $445.0 million and $470.0 million, net loss between ($10.6) million and $4.6 million, and adjusted net loss between ($8.1) million and $7.1 million. EBITDA is projected to be between $5.8 million and $25.0 million, and Adjusted EBITDA between $15.8 million and $35.0 million.

Management Comments

• Gary S. Gillheeney, Sr., President and Chief Executive Officer, stated that the company delivered a strong start to 2024 with first quarter revenue exceeding the high-end of their revenue guidance.
• Mr. Gillheeney, Sr. expressed confidence that the MACs prioritization of demonstrated clinical efficacy will strengthen their competitive position over the long term.
• Mr. Gillheeney, Sr. is optimistic about the company's expansion opportunities in a significant new addressable market.

Industry Context

The company operates in the regenerative medicine space, focusing on advanced wound care and surgical & sports medicine. The results reflect the competitive landscape and the challenges of navigating reimbursement and regulatory environments. The company's focus on clinical efficacy aligns with industry trends emphasizing value-based healthcare.

Comparison to Industry Standards

• Organogenesis competes with companies like Smith & Nephew, Integra LifeSciences, and Acelity in the advanced wound care market.
• While Organogenesis saw a 2% increase in overall revenue, some competitors have reported higher growth rates in specific segments.
• The decrease in Surgical & Sports Medicine revenue contrasts with some competitors who have seen growth in this area.
• The company's adjusted EBITDA margin of 2.4% is lower than some industry benchmarks, indicating potential areas for improvement in operational efficiency.
• The company's focus on the ReNu program for knee OA aligns with a growing trend in regenerative medicine for addressing musculoskeletal conditions.

Stakeholder Impact

• Shareholders may react positively to the reaffirmed revenue guidance but negatively to the decrease in adjusted EBITDA.
• Employees may be impacted by the company's restructuring activities.
• Customers will continue to have access to the company's products.
• Suppliers will continue to provide materials for the company's products.
• Creditors will be monitoring the company's debt obligations.

Next Steps

• Management will host a conference call on May 9th to discuss the results and provide a corporate update.
• The company will continue to focus on its ReNu program and expansion opportunities.
• The company will work to achieve its full-year 2024 financial guidance.

Key Dates

Keywords

Organogenesis, Regenerative Medicine, Wound Care, Surgical, Sports Medicine, Financial Results, Net Revenue, EBITDA, Net Loss, Guidance